All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Role of strontium ranelate in the therapy of osteoporosis

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73580907" target="_blank" >RIV/61989592:15110/17:73580907 - isvavai.cz</a>

  • Alternative codes found

    RIV/00098892:_____/17:N0000085

  • Result on the web

    <a href="http://dx.doi.org/10.23937/2469-5726/1510050" target="_blank" >http://dx.doi.org/10.23937/2469-5726/1510050</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.23937/2469-5726/1510050" target="_blank" >10.23937/2469-5726/1510050</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Role of strontium ranelate in the therapy of osteoporosis

  • Original language description

    Strontium ranelate is a medicine used to treat postmenopausal osteoporosis in women and osteoporosis in men. Preclinical data suggest its dual effect consisting of the control of bone resorption and promotion of bone formation. Admininstration of strontium ranelate leads to significant increase in the bone mass. Changes in bone density can be used to evaluate the adherence of patients as well as, in case of strontium ranelate, to etimate the fracture risk reduction. Clinical studies demonstrated its effect on reducing the risk of both vertebral and non-vertebral fractures, including fractures of the proximal femur. Currently, it is a second-line treatment of osteoporosis administered in case of intolerance, failure or contraindication of other therapy. Recently its cardiovascular safety was discussed. Contraindications of strontium ranelate in patients with ischemic heart disease, peripheral arterial desease, cerebrovascular disease or uncontrolled hypertension were added in 2013 to the wording of the Summary of Product Characteristics (SPC). Cohort and observational studies, however, did not clearly confirm the cardiovascular risk associated with administration of strontium ranelate. It is still a medicine indicated for treatment of osteoporosis with a favourable risk and benefit ratio.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>ost</sub> - Miscellaneous article in a specialist periodical

  • CEP classification

  • OECD FORD branch

    30218 - General and internal medicine

Result continuities

  • Project

  • Continuities

    S - Specificky vyzkum na vysokych skolach

Others

  • Publication year

    2017

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of Rheumatic Diseases and Treatment

  • ISSN

    2469-5726

  • e-ISSN

  • Volume of the periodical

    3

  • Issue of the periodical within the volume

    2

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    6

  • Pages from-to

    1-6

  • UT code for WoS article

  • EID of the result in the Scopus database